Maikel Wijsbek’s Post

View profile for Maikel Wijsbek, graphic

Supporting clients with global mobility tax and social security challenges.

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

How biotech companies are standing out during JPM Week

How biotech companies are standing out during JPM Week

kpmg.voicestorm.com

To view or add a comment, sign in

Explore topics